

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong under the Companies Ordinance)

(Stock code: 1093)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) hereby announces that Mr. LI Chunlei (“**Mr. LI**”) was appointed as an executive director of the Company with effect from 12 December 2017.

Mr. LI, aged 41, joined the Group in 2004 and is currently the Chief Scientist of the Group in charge of research and development. Mr. LI is also the general manager of a subsidiary of the Company, deputy director of the Novel Pharmaceutical Preparations and Excipients State Key Laboratory and director of the Hebei Pharmaceutical Engineering Technology Centre. Mr. LI holds a bachelor’s degree in engineering (biological pharmaceuticals) from Jilin University and Shenyang Pharmaceutical University, a master’s degree in science (microbial and biochemical pharmaceuticals) from Jilin University and a doctorate in science (pharmaceutical science) from Shenyang Pharmaceutical University. Mr. LI is mainly engaged in the research, development and commercialisation of nano drugs, and has been responsible for the research and development of approximately 20 nano drugs including “Duomeisu” (doxorubicin hydrochloride liposome injection) and paclitaxel albumin-bound nano particles.

Mr. LI is currently a member of the Pharmaceutical Preparations Professional Committee and Nano Drugs Professional Committee established by Chinese Pharmaceutical Association; and also an executive member of the Nano Biotech Sub-committee established by the China Medicinal Biotech Association.

Mr. LI has entered into a service contract with the Company for a period of three years commencing from 12 December 2017 and his appointment is subject to retirement and re-election at the annual general meeting in accordance with the articles of association of the Company. Mr. LI is entitled to receive a monthly salary of RMB52,500 and an annual director’s fee of HK\$60,000. He is also eligible to receive performance related discretionary bonus to be determined by the Board. His emoluments were determined having giving consideration to the prevailing market practice, the Company’s remuneration policy and his level of responsibility.

Mr. LI does not have any relationships with any directors, senior management or substantial or controlling shareholders of the Company, and has not held any directorships in any listed public companies in the last three years. As at the date of this announcement, Mr. LI does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed above, there is no other information to be disclosed pursuant to rule 13.51(2) of

the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited and there is no other matter which needs to be brought to the attention of the shareholders of the Company in connection with the appointment of Mr. LI.

The Board wishes to take this opportunity to warmly welcome Mr. LI to join the Board.

By order of the board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 12 December 2017

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. PAN Weidong, Mr. WANG Huaiyu, Mr. WANG Zhenguo, Mr. WANG Jinxu, Mr. LU Hua, Mr. LI Chunlei and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.